These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1252 related articles for article (PubMed ID: 21816786)

  • 1. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
    Olson EJ; Pearce GL; Jones NP; Sprecher DL
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.
    Hughes TA; Stentz F; Gettys T; Smith SR
    Metabolism; 2006 Jan; 55(1):26-34. PubMed ID: 16324916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
    Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
    J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
    Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
    Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency.
    Ikewaki K; Nishiwaki M; Sakamoto T; Ishikawa T; Fairwell T; Zech LA; Nagano M; Nakamura H; Brewer HB; Rader DJ
    J Clin Invest; 1995 Sep; 96(3):1573-81. PubMed ID: 7657828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of short- and long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects.
    Kearney T; de Gallegos CN; Proudler A; Parker K; Anayaoku V; Bannister P; Venkatesan S; Johnston DG
    Metabolism; 2003 Jan; 52(1):50-9. PubMed ID: 12524662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
    Chan DC; Nguyen MN; Watts GF; Barrett PH
    J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.
    Chan DC; Hoang A; Barrett PH; Wong AT; Nestel PJ; Sviridov D; Watts GF
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1658-66. PubMed ID: 22745238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.
    Risérus U; Sprecher D; Johnson T; Olson E; Hirschberg S; Liu A; Fang Z; Hegde P; Richards D; Sarov-Blat L; Strum JC; Basu S; Cheeseman J; Fielding BA; Humphreys SM; Danoff T; Moore NR; Murgatroyd P; O'Rahilly S; Sutton P; Willson T; Hassall D; Frayn KN; Karpe F
    Diabetes; 2008 Feb; 57(2):332-9. PubMed ID: 18024853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
    Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
    J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
    Chan DC; Watts GF; Nguyen MN; Barrett PH
    Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women.
    Chiuve SE; Martin LA; Campos H; Sacks FM
    J Clin Endocrinol Metab; 2004 May; 89(5):2207-13. PubMed ID: 15126543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.